Startups
KYAN has developed an AI-enabled personalised medicine platform for cancer treatment that utilises proprietary hardware and AI/ ML to optimise the best possible drug/ dose combination, offering it as a clinical decision-making tool for physicians to prescribe treatment.
Website
Website
Overview
Employees
1-10
Founded date
2016
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 27, 2022 | KYAN Therapeutics raises USD $5.0M for its Pre-Series A funding | Singapore headquartered KYAN to launch personalized treatment assay for cancer patients following publication of landmark study with leading cancer centers SINGAPORE, October 27, 2022 /EINPresswire.com/ -- KYAN Therapeutics, a biotech compa... |
| Oct 19, 2022 | Publication of Clinical Study Shows Positive Benefits of KYAN's Clinical Decision Support Platform for Cancer Patients | In largest prospective study to date of guided therapy for relapsed/refractory non-Hodgkin lymphoma patients, 59% had improved PFS over their previous treatment SINGAPORE, October 19, 2022 /EINPresswire.com/ -- KYAN Therapeutics, a biotech ... |
| Oct 6, 2022 | KYAN Therapeutics Announces Presentation of Clinical Utility of Ex-Vivo Platform at ASTRO and CTOS by Collaborators | SINGAPORE, October 6, 2022 /EINPresswire.com/ -- Data on the feasibility of identifying therapeutic options in head and neck cancers and sarcoma with KYAN’s analytical ex vivo drug screening platform will be presented at the Annual Meetings... |
| Sep 17, 2022 | KYAN Therapeutics' technology platform identifies novel and effective nucleic acid therapies for MYC-driven liver cancer | Study published in Bioengineering & Translational Medicine SINGAPORE, SINGAPORE, September 17, 2022 /EINPresswire.com/ -- MYC is a transcription factor that is dysregulated in over 70% of human cancers, making it an important target tha... |
| May 9, 2022 | KYAN Therapeutics and Curie Oncology Announce Strategic Collaboration to Provide Personalized Cancer Test in Singapore | From left to right: Dr Toh Chee Keong (Curie Oncology), Hugo Saavedra (KYAN CEO), Masturah Rashid (KYAN Head of R&D) and Bo Hong Tay (Curie Oncology) KYAN Therapeutics uses small data AI in a proprietary phenotypic drug sensitivity assa... |
| Apr 28, 2022 | KYAN Therapeutics and Aesculape CRO Partner to Offer Drug Development Biopharma Services | From left to right: Masturah Rashid (KYAN Head of R&D), Hugo Saavedra (KYAN CEO), Jean Paul Deslypere (Aesculape CEO) and Edward Chow (KYAN Chief Scientific Advisor) SINGAPORE, April 28, 2022 /EINPresswire.com/ -- KYAN Therapeutics, Inc... |
| Feb 14, 2017 | The opportunities and challenges of AI in health care | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! When we asked dozens of venture capitalists where... |
| KYAN Therapeutics | “KYAN’s mission is to BRIDGE THE CANCER CARE GAP by advancing revolutionary technologies” | |
| Will AI-Integrated Wellness Replace the 'Life Coach?' | This is the web version of dot.LA’s daily newsletter. Sign up to get the latest news on Southern California’s tech, startup and venture capital scene. According to Bloomberg, Apple is developing an AI-powered health coaching service, along ... |
Reviews 0
FAQ about KYAN Technologies
When was KYAN Technologies founded?
KYAN Technologies was founded in 2016.
What has the press written about KYAN Technologies?
Parsers VC has collected 10 articles mentioning KYAN Technologies, among them “KYAN Therapeutics raises USD $5.0M for its Pre-Series A funding” (Oct 27, 2022) and “Publication of Clinical Study Shows Positive Benefits of KYAN's Clinical Decision Support Platform for Cancer Patients” (Oct 19, 2022).
Is KYAN Technologies still active?
Yes, KYAN Technologies is active; its latest activity on Parsers VC dates from May 29, 2023.